Seattle Genetics and Astellas have filed their antibody-drug conjugate enfortumab vedotin with the US drug regulator for advanced bladder cancer, after failure of chemotherapy and immunothe
Germany’s Boehringer Ingelheim has bought the Swiss biotech AMAL Therapeutics, a privately-held Swiss biotech focused on immunotherapy and vaccines in oncology.
Virus-based immunotherapy biotech Transgene is to begin clinical trials of its head and neck cancer drug candidate TG4050 after gaining regulatory clearance from the UK regulator.<
